EMBC INVESTOR DEADLINE: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit-- HBSS

Embecta Corp. ( NASDAQ: EMBC ) faces a securities class action lawsuit, which seeks to represent investors who purchased or acquired Embecta common stock between November 25, 2025 and May 4, 2026. The lawsuit follows the company's disastrous Q2 2026 earnings report, apparently at odds with prior narrative, which triggered a massive selloff in the stock and analysts' questions. These developments have prompted national shareholder rights firm Hagens Berman to open an investigation into claims that Embecta violated the federal securities laws. The firm encourages Embecta investors who suffered substantial losses to submit your losses now . Class Period: Nov. 25, 2025 – May 4, 2026 Lead Plaintiff Deadline: Aug. 17, 2026 Visit: www.hbsslaw.com/investor- fraud /embc Contact the Firm Now: [email protected] 844-916-0895 Embecta Corp. (EMBC) Securities Class Action: Embecta is a global medical device company whose core business product is pen needles – sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. In the past, pen needle revenues have comprised over 70% of the company's total revenues. The litigation's primary focus is on the propriety of Embecta's Class Period repeated assurances that "insulin pens have been stable […] showing the underlying resilience and the durability of that portfolio[]" and "our pen needle business is incredibly resolute." This narrative formed the basis for the company's February 5, 2026 guidance reiterating 2026 adjusted EPS of $2.80 - $3.00. The company also touted maintenance of its dividend within its capital allocation plans as a return of capital to shareholders. The complaint alleges the company's assurances and guidance were misleading when given because Embecta knew or recklessly disregarded that weaknesses in the pen needle market was likely to significantly disrupt the company's annual guidance...